155 related articles for article (PubMed ID: 28232048)
21. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
[TBL] [Abstract][Full Text] [Related]
22. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.
Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
[TBL] [Abstract][Full Text] [Related]
23. CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer.
Ni S; Wang H; Zhu X; Wan C; Xu J; Lu C; Xiao L; He J; Jiang C; Wang W; He Z
Oncotarget; 2017 Jan; 8(5):8010-8021. PubMed ID: 28030829
[TBL] [Abstract][Full Text] [Related]
24. Metronomics chemotherapy: time for computational decision support.
Barbolosi D; Ciccolini J; Meille C; Elharrar X; Faivre C; Lacarelle B; André N; Barlesi F
Cancer Chemother Pharmacol; 2014 Sep; 74(3):647-52. PubMed ID: 25082520
[TBL] [Abstract][Full Text] [Related]
25. Chronic stress increases experimental pancreatic cancer growth, reduces survival and can be antagonised by beta-adrenergic receptor blockade.
Partecke LI; Speerforck S; Käding A; Seubert F; Kühn S; Lorenz E; Schwandke S; Sendler M; Keßler W; Trung DN; Oswald S; Weiss FU; Mayerle J; Henkel C; Menges P; Beyer K; Lerch MM; Heidecke CD; von Bernstorff W
Pancreatology; 2016; 16(3):423-33. PubMed ID: 27083074
[TBL] [Abstract][Full Text] [Related]
26. Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse Model.
Bill R; Fagiani E; Zumsteg A; Antoniadis H; Johansson D; Haefliger S; Albrecht I; Hilberg F; Christofori G
Clin Cancer Res; 2015 Nov; 21(21):4856-67. PubMed ID: 26206868
[TBL] [Abstract][Full Text] [Related]
27. Mitochondrial uncoupling protein 2 and pancreatic cancer: a new potential target therapy.
Donadelli M; Dando I; Dalla Pozza E; Palmieri M
World J Gastroenterol; 2015 Mar; 21(11):3232-8. PubMed ID: 25805929
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and predictive markers in pancreatic adenocarcinoma.
Le N; Sund M; Vinci A;
Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
[TBL] [Abstract][Full Text] [Related]
29. Metronomic chemotherapy and immunotherapy in cancer treatment.
Chen YL; Chang MC; Cheng WF
Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
[TBL] [Abstract][Full Text] [Related]
30. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
[TBL] [Abstract][Full Text] [Related]
31. IL24 and its Receptors Regulate Growth and Migration of Pancreatic Cancer Cells and Are Potential Biomarkers for IL24 Molecular Therapy.
Jia Y; Ji KE; Ji J; Hao C; Ye L; Sanders AJ; Jiang WG
Anticancer Res; 2016 Mar; 36(3):1153-63. PubMed ID: 26977011
[TBL] [Abstract][Full Text] [Related]
32. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway.
Liu X; Xiao XY; Shou QY; Yan JF; Chen L; Fu HY; Wang JC
J Ethnopharmacol; 2016 Dec; 193():538-545. PubMed ID: 27686271
[TBL] [Abstract][Full Text] [Related]
33. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW
Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172
[TBL] [Abstract][Full Text] [Related]
34. Metronomic scheduling: the future of chemotherapy?
Gasparini G
Lancet Oncol; 2001 Dec; 2(12):733-40. PubMed ID: 11902515
[TBL] [Abstract][Full Text] [Related]
35. Pancreatic Neoplasms and Autophagy.
Barton LA; Ren J
Curr Drug Targets; 2018; 19(9):1018-1023. PubMed ID: 27358060
[TBL] [Abstract][Full Text] [Related]
36. Metronomic chemotherapy using orally active carboplatin/deoxycholate complex to maintain drug concentration within a tolerable range for effective cancer management.
Mahmud F; Chung SW; Alam F; Choi JU; Kim SW; Kim IS; Kim SY; Lee DS; Byun Y
J Control Release; 2017 Mar; 249():42-52. PubMed ID: 28093298
[TBL] [Abstract][Full Text] [Related]
37. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
38. Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules.
Banchi M; Cox MC; Bocci G
Cancer Lett; 2024 Jun; 591():216900. PubMed ID: 38636896
[TBL] [Abstract][Full Text] [Related]
39. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy.
Kashiwagi H; McDunn JE; Simon PO; Goedegebuure PS; Xu J; Jones L; Chang K; Johnston F; Trinkaus K; Hotchkiss RS; Mach RH; Hawkins WG
Mol Cancer; 2007 Jul; 6():48. PubMed ID: 17631687
[TBL] [Abstract][Full Text] [Related]
40. Triple-amiRNA VEGFRs inhibition in pancreatic cancer improves the efficacy of chemotherapy through EMT regulation.
Huang J; Mei H; Tang Z; Li J; Zhang X; Lu Y; Huang F; Jin Q; Wang Z
J Control Release; 2017 Jan; 245():1-14. PubMed ID: 27889393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
